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Background: Treatment variation is an important issue in health care provision. An external peer review
programme for multidisciplinary cancer care was introduced in 1994 in the Netherlands to improve the
multidisciplinary organisation of cancer care in hospitals.
So far the clinical impact of external quality assessment programmes such as external peer review and accreditation
remains unclear. Our objective was to examine the degree of variation in treatment patterns and the possible effect
of external peer review for multidisciplinary cancer care for breast cancer patients.
Methods: Patients with breast cancer were included from 23 hospitals from two ‘intervention regions’ with the
longest experience with the programme and 7 hospitals that never participated (control group). Data on tumour and
treatment characteristics were retrieved from the Netherlands Cancer Registry. Treatment modalities investigated were:
the completeness of breast conserving therapy, introduction of the sentinel node biopsy, radiotherapy after breast
conserving surgery for ductal carcinoma in situ (DCIS), adjuvant radiotherapy for locally advanced breast cancer (T3/M0
or any T,N2-3/M0), adjuvant chemotherapy for early stage breast cancer (T1-2/N+/M0) and neo-adjuvant chemotherapy
for T4/M0 breast cancer. Hospitals from the two intervention regions were dichotomised based on their implementation
proportion (IP) of recommendations from the final reports of each peer review (high IP vs. low IP). This was regarded as
a measure of how well a hospital participated in the programme.
Results: 63,516 female breast cancer patients were included (1990-2010). Variation in treatment patterns was observed
between the intervention regions and control group. Multidisciplinary treatment patterns were not consistently better
for patients from hospitals with a high IP.
Conclusions: There is no relationship between the external peer review programme for multidisciplinary cancer care
and multidisciplinary treatment patterns for breast cancer patients. Regional factors seem to exert a stronger effect on
treatment patterns than hospital participation in external peer review.
Keywords: Breast neoplasms, Cohort studies, Healthcare quality assessment, Quality improvement, Peer reviewBackground
Breast cancer is the commonest cancer in women in the
Netherlands and its burden increased during the last
decades due to a steady rise in incidence [1]. Survival
rates have improved because of better imaging and
detection techniques, screening programmes and the* Correspondence: m.kilsdonk@iknl.nl
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unless otherwise stated.introduction of new therapies [2,3]. Breast cancer
treatment is marked by a multidisciplinary approach
and specialisation of the involved medical and nursing
specialists. A recent study in 13,722 women showed
that improving multidisciplinary care was associated
with improved survival and reduced variation in survival
among hospitals [4]. Specialisation of physicians is an
important component of multidisciplinary care and is
associated with better outcomes for various cancers
[5]. A study in the UK revealed an 11-17% reduction
in risk of death in women treated for breast cancerl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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were seen in other types of cancer and during the 90’s
multidisciplinary care became the standard of cancer care.
It is known that treatment variation exists between and
within countries and it is unknown whether and how
these differences interact with improvement efforts. This
poses serious challenges in efforts to evaluate quality
improvement programmes.
Several quality improvement methods are used to
improve the multidisciplinary organisation of care and
reduction of variation. In the Netherlands an external
peer review programme was introduced in 1994.
Designed and executed by medical and nursing cancer
specialists, it was introduced in the Northern Netherlands
and gradually spread over the entire country. The
programme focuses on the organisational conditions to
provide optimal cancer care. Participation is voluntary and
hospitals are advised to participate in cycles of 4–5 years.
After a self-assessment, on-site observation and interviews,
the organisation of cancer care in a hospital is evaluated
and recommendations for improvement are given. Major
topics of recommendations were the organisation of weekly
multidisciplinary patient care meetings, shared decision
making between specialists, oncological specialisation of
medical specialists, dedication of oncology committees
(with representatives of all medical specialisms) to policy
making, referral policies for rare tumours and highly
complicated interventions, introduction of integrated
care pathways and working to evidence based guidelines.
More information on the programme can be found in
Additional file 1.
In general, the clinical impact of external peer review
remains under-investigated. A study evaluating a peer
review programme for chronic obstructive pulmonary
disease in the United Kingdom found an association
with improved quality of care, service delivery and
changes that promote quality improvement after three
years [7]. The evaluation after one year revealed no
differences showing that changes in healthcare can take
a prolonged period to occur [8]. Accreditation is the most
frequently studied form of external quality assessment.
Literature reviews on the effects of accreditation on the
quality of care could not provide strong evidence due to
limitations of the studies [9,10]. The programmes demand
high financial and labour investments and therefore there
is a need for more research on the clinical impact of these
programmes [11,12].
The purpose of our study was to investigate the
multidisciplinary treatment patterns of breast cancer
patients and the effect of the external peer review
programme for multidisciplinary cancer care in general
hospitals. In a previous study we found some positive
effects on colorectal cancer treatment, but the results
needed to be interpreted cautiously due to the ambiguityof the outcomes and possible confounding factors [13]. In
the current study we examined whether our previous
results are also evident in breast cancer treatment. More
importantly, by analysing different regions separately
we hope to gain more insights in possible regional
confounders. We hypothesised that the willingness of
a hospital to have external peer review and to follow the
recommendations from it, is correlated to the hospital
giving higher quality of breast cancer treatment measured
by the introduction of new multidisciplinary therapies.
Methods
Design and patients
Only female patients diagnosed with primary epithelial
breast cancer (ICD-O 10, International Classification of
Diseases, codes: C50.0 to 50.9) between 1 January 1990 and
31 December 2010 were selected from the Netherlands
Cancer Registry (NCR). This is a population based
independent cancer registry containing clinical administra-
tive data of every newly diagnosed cancer patient in the
Netherlands. Data is collected directly from the hospitals’
patient files by specially trained registration clerks.
Topography and morphology is coded according to the
International Classification of Diseases for Oncology
(ICD-O) and staging according to the TNM-classification.
Follow-up of vital status is achieved by linkage of the
registry to municipal records. The quality of the data
is high [14] and completeness is estimated to be at
least 95% [15].
Patients were included from hospitals in the Northern
Netherlands and the Rotterdam region. In these regions
the external peer review programme was introduced first
(intervention regions). Patients from hospitals from
other regions that never participated before 2009 were
included in the control group. We excluded patients that
were diagnosed with neuroendocrine tumours, synchronous
tumours, diagnosed at autopsy and that had any type of
previous malignancy.
Hospital categories
Hospitals from the intervention group were categorised by
the implementation proportion (IP) of recommendations
that were given in the final reports of each peer review. We
dichotomised the intervention region hospitals by their IP
(high IP vs. low IP, no threshold was used). We regarded
the IP of the recommendations as a proxy of how
well a hospital participated in the programme. Rating
the implementation was performed by studying final
reports from subsequent reviews, follow-up correspond-
ence, hospital documents and interviews with stakeholders
when necessary. Implementation of a recommendation was
ranked on a scale from 0 to 4 (Table 1). The IP per hospital
was expressed as a percentage of the total possible score.
When implementation of a recommendation could not be
Table 1 Criteria and (real) examples of the ranking of implementation of the recommendations on a scale from 0-4
Implementation
score
Criteria Recommendation Follow up report
0 Not implemented at all
1 Hospital only started working on
implementing
The oncology committee should
make oncological policy plans
An oncological policy plan is in preparation
2 A recommendation consists of
two parts and one is implemented
An oncology committee needs to
be formed consisting of physicians
and a nursing staff representative
There is an oncology committee consisting of
physicians but no nursing staff representative
3 Recommendation is implemented
but not yet in the entire organisation
There should be oncological
specialisation, especially amongst
the surgeons, urologists and
gynacologists
Oncological specialisation was realised in
surgery, gynaecology, internal and pulmonary
medicine but not in urology.
4 Complete implementation The hospital should have a fulltime
pulmonary physician if lung surgery
is performed for an optimal pre-,
peri- and post-operative care
The hospital appointed a full-time pulmonary
physician
Kilsdonk et al. BMC Cancer 2014, 14:596 Page 3 of 8
http://www.biomedcentral.com/1471-2407/14/596determined (lost to follow-up), this recommendation was
subtracted from the total possible score. The average IP of
all peer reviews per hospital was used because it is not
known what the time period is in which changes based on
organisational change can occur and quality improvement
is a continuous process. Ranking the implementation
of recommendations was performed by the principal
investigator. If e.g. the report from the next peer-review
states that a recommendation was not implemented at all
this was ranked as zero. Full implementation was ranked
as 4, examples of recommendations and their ranking can
be seen in Table 1. Due to the objective nature of the
evidence the ranking was not considered to be arbitrarily
and we did not use an inter-rater approach.
From the hospitals in the two intervention regions we
used data from two or three cycles of participation:
– Northern Netherlands: three cycles, 1994–2009.
– Rotterdam region: two cycles, 1996–2006. A third
cycle was completed between 2009 and 2011 but
follow-up time was too short to monitor the IP.
All hospitals in these regions voluntarily participated
in the peer review programme. The university medical
centres and hospitals that merged during our study
period were excluded, because it was impossible to
follow-up the recommendations. Hospitals were asked
to participate in the study by giving permission to use
their data from the NCR and final reports.
Analyses
We analysed the Northern Netherlands and Rotterdam
region separately to gain more insights in possible
regional confounders besides the external peer review
programme. Patients were grouped according to the
hospital in which the diagnosis was made. They may have
been referred for treatment but this was regarded to begood clinical practice (and referral policy is a theme of the
programme). Multivariate logistic analysis was used to
analyse treatment variation and the influence of hospital
category (based on IP), gender, age at diagnosis, year of
diagnosis, average hospital volume of diagnoses and
presence of an in-hospital radiotherapy department.
We studied several multidisciplinary treatment modalities.
First of all, we studied the completeness of breast conserving
therapy (BCT). From its introduction onwards, breast
conserving therapy is a multidisciplinary procedure
and one of the earliest examples of multidisciplinary
cancer treatment. Breast conserving surgery (BCS) was
initially complemented with axillary lymph node dissection
(ALND) and radiotherapy. Omission of lymph node dissec-
tion is allowed after a negative sentinel node biopsy (SNB).
In our analyses, BCT was considered complete if radiother-
apy had been given and ALND was performed or when
radiotherapy is given, SNB was performed and ALND was
omitted. We separately analysed the introduction of the
sentinel node biopsy. Other indicators for treatment vari-
ation were taken from the indicator list defined by the
NABON (National Breast Cancer Network Netherlands) in
2009. This list is part of a national audit on the quality of
breast cancer diagnostics and treatment (NBCA) that
started in 2011 [16]. These indicators are: radiother-
apy after BCS for ductal carcinoma in situ (DCIS),
adjuvant radiotherapy for locally advanced breast cancer
(T3/M0 or any T,N2-3/M0), adjuvant chemotherapy for
early stage breast cancer (T1-2/N+/M0) and neo-adjuvant
chemotherapy for T4/M0 breast cancer. Although the
NBCA was established in 2011, data on the selected indica-
tors were available since 1990. We could therefore look in
retrospect at the period from 1990 onwards to evaluate how
hospitals performed on these quality indicators that we now
regard to be the standard of care for breast cancer patients.
For the analyses of completeness of breast conserving
therapy and adjuvant chemotherapy for early stage breast
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clinical stage if pathological stage was unknown. For
the rest of the analyses clinical stage was used
substituted by pathological stage if unknown. STATA
version 12.0 was used for all analyses. Written syntaxes
guarantee reproducibility of the results. P values were
considered significant if smaller than 0.05.
Results
Hospitals and recommendations
Twenty-six hospitals from the Northern Netherlands
and Rotterdam region were asked to give permission to
use the data from their peer reviews and the Netherlands
Cancer Registry. Twenty-three gave permission: 13 hospitals
from the Northern Netherlands and 10 from the Rotterdam
region. Seven out of twelve hospitals without experience
with the programme agreed to be included in the control
group. In total, our study includes patient data from
30 hospitals, approximately one-third of all hospitals
in the Netherlands. In the three cycles of peer review
in the Northern Netherlands and two cycles in the
Rotterdam region 727 recommendations were given,
averaging 12 recommendations per peer review per
hospital. The intervention hospitals in both regions were
dichotomised based on the IP of the recommendations.
The Northern Netherlands region was divided in 6 hospitalsTable 2 Characteristics of the study cohort
Variable North high
IP N(%)
No
low
6 hospitals 7 h
Mean age at diagnosis 61.16 61
SD 14.16 SD
Period of diagnosis
1990-1995 3260 (23.21) 20
1996-2001 4079 (29.05) 30
2002-2007 4426 (31.52) 35
2008-2010 2278 (16.22) 20
Stage
IS 1097 (7.81) 77
1 4758 (33.88) 36
2 5881 (41.88) 45
3 1480 (10.54) 11
4 718 (5.11) 54
X 109 (0.78) 10
Average annual volume of hospital of diagnosis
<50 924 (6.58) 64
50-100 4226 (30.09) 10
100 or more 8893 (63.33) 0 (
Characteristics of breast cancer patients according to the hospital category, 1990–2
recommendations given in the programme.with a high IP (average IP 63.2%) and 7 hospitals with
a low IP (average IP 48.9%). The Rotterdam region was
dichotomised in 5 hospitals with a high IP (average IP
63.2%) and 5 with a low IP (average 41.4%).
Patients
Our total cohort consists of 63,516 women. Table 2
shows the characteristics of the population grouped by
their hospital category. There were no large differences
in mean age at diagnosis and the number of patients per
period of diagnosis between patients diagnosed in the
different hospital categories. The average annual case
volume differs between the regions, as in the Rotterdam
region no hospitals with less than 50 patients diagnosed
annually existed in the period under study. For only two
hospital categories hospitals with more than 100 diagnosis
per year existed (Northern Netherlands high IP and
control group, Table 2).
Completeness of breast conserving therapy
Incomplete breast conserving therapy, omitting radiother-
apy and/or ALND after breast conserving surgery rarely
occurred (Table 3). Although the absolute risk is low, the
odd’s ratio’s show that the odd’s of receiving complete
BCT were higher in both hospital categories in the
Northern Netherlands.rth
IP N(%)
Rotterdam
high IP N(%)
Rotterdam
low IP N(%)
Controls N(%)
ospitals 5 hospitals 5 hospitals 7 hospitals
.48 61.33 61.40 59.80
14.20 SD 14.34 SD 14.39 SD 13.67
95 (19.42) 2310 (23.16) 2249 (23.28) 4454 (23.38)
85 (28.60) 2717 (27.24) 2635 (27.28) 5131 (26.93)
58 (32.98) 3082 (30.90) 3044 (31.51) 5995 (31.47)
50 (19.00) 1866 (18.71) 1732 (17.93) 3470 (18.22)
6 (7.19) 794 (7.96) 775 (8.02) 1577 (8.28)
60 (33.93) 3323 (33.31) 3249 (33.63) 6595 (34.62)
75 (42.41) 4243 (42.54) 4097 (42.41) 7898 (41.46)
23 (10.41) 1018 (10.21) 959 (9.93) 1835 (9.63)
7 (5.07) 513 (5.14) 487 (5.04) 877 (4.60)
7 (0.99) 84 (0.84) 93 (0.96) 268 (1.41)
7 (6.00) 0 (0.00) 0 (0.00) 953 (5.00)
141 (94.00) 9975 (100) 9660 (100) 16.579 (87.03)
0.00) 0 (0.00) 0 (0.00) 1518 (7.97)
010, data are no (%), N = 63,516. IP = Implementation Proportion of
Table 3 Chances of receiving multidisciplinary treatment
Treatment Hospital category % of patients treated according to
guidelines
OR 95% CI
‘90-‘95 ‘96-‘01 ‘02-‘07 ‘08-‘10
Complete breast conserving treatment. N = 22453 Controls 95.6 92.3 93.4 95.8 1.00 Reference
Inclusion criteria: Stage I-IIIA North High IP 97.8 97.1 97.8 98.3 2.68* 2.08-3.45
Exclusion criterium: Breast amputation after BCS North Low IP 95.4 96.3 96.7 97.1 1.77* 1.43-2.17
Rotterdam High IP 93.0 88.9 91.9 96.7 0.77* 0.64-0.92
Rotterdam Low IP 94.6 89.6 91.7 95.0 0.72* 0.60-0.85
Introduction of the SNB. N = 25612 Controls 0 33.9 93.6 98.3 1.00 Reference
Inclusion criteria: cT1-2, cN0, cM0, BCS North high IP 0 16.2 93.9 98.8 0.68* 0.55-0.84
North low IP 0 20.9 93.2 98.2 0.59* 0.50-0.70
Rotterdam high IP 0 19.1 89.0 98.8 0.46* 0.38-0.55
Rotterdam low IP 0 14.8 92.1 96.9 0.48* 0.40-0.57
Radiotherapy after BCS for DCIS. N = 2414 Controls 16.1 31.7 76.8 85.2 1.00 Reference
Inclusion criteria: DCIS, BCS North high IP 50.0 49.0 74.8 84.9 1.24 0.88-1.74
North low IP 57.1 43.7 72.5 81.7 1.13 0.84-1.52
Rotterdam high IP 33.3 48.9 72.0 79.8 1.08 0.79-1.49
Rotterdam low IP 27.6 50.4 74.1 83.3 1.27 0.93-1.73
Adjuvant radiotherapy locally advanced breast cancer N = 1511 Controls 64.6 67.3 64.6 69.1 1.00 Reference
Inclusion criteria: cT3,anyN,M0 and any T,N2-3,M0 + amputation North high IP 53.5 54.4 53.5 68.3 0.75 0.51-1.10
North low IP 46.2 62.5 46.2 53.2 0.56* 0.39-0.80
Rotterdam high IP 39.2 34.2 39.2 61.5 0.40* 0.29-0.55
Rotterdam low IP 29.7 35.9 29.7 68.6 0.36* 0.25-0.52
Adjuvant chemotherapy early stage breast cancer. N = 9511 Controls 51.3 73.1 85.1 91.9 1.00 Reference
Inclusion criteria: pT1-2 M0/X, surgery age < 60 North high IP 62.3 69.7 90.4 93.0 1.24 1.00-1.54
North low IP 52.8 70.6 91.4 91.3 1.29* 1.07-1.54
Rotterdam high IP 60.2 72.3 88.0 95.6 1.50* 1.26-1.81
Rotterdam low IP 55.3 67.2 90.1 96.0 1.22* 1.01-1.46
Neo-adjuvant chemotherapy T4/M0 breast cancer. N = 1484 Controls 5.1 27.4 34.5 61.9 1.00 Reference
Inclusion criteria: cT4NxM0, surgery North high IP 11.2 25.0 56.0 65.3 1.24 0.73-2.09
North low IP 4.8 22.8 57.8 44.0 1.57* 1.00-2.47
Rotterdam high IP 6.7 28.0 55.0 51.9 2.67* 1.74-4.07
Rotterdam low IP 5.3 29.2 54.8 61.5 2.02* 1.32-3.08
Odd’s ratio’s for receiving multidisciplinary therapy per hospital category. Adjusted for age, year of incidence, annual volume of diagnoses per hospital, stage
(if necessary). 1990–2010 *P < 0.05. IP = implementation proportion of recommendations given in the programme.
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Since 2003 guidelines recommend the SNB to be performed
in T1-2/N0 breast cancer. Unfortunately, the SNB was not
registered consistently in the NCR in some regions of the
country. When an ALND was performed after SNB then
only the ALND has been registered in these regions. This
might give an underestimation of the group that had a BCT
with SNB followed by ALND. In our study, this only
concerns the control group. We excluded all patients
from the control group that were diagnosed in hospitals
with this deviating registration policy (N = 1950). The
control group remained the largest group. Patients inthe control region were more likely to receive a sentinel
node biopsy compared to both intervention regions. The
differences were most prominent between 1996–2001
(Table 3).
Radiotherapy after BCS for DCIS
The total numbers of patients are low in the early
periods. After the introduction of a nationwide screening
programme the incidence of DCIS has gradually risen
because of the increasing quality of diagnostics. In the
latest time period the percentage of radiotherapy was over
79% in all hospital categories. No significant differences
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the different hospital categories (Table 3).
Adjuvant radiotherapy for locally advanced breast cancer
Official guideline introduction of adjuvant radiotherapy for
locally advanced breast cancer (T3/M0 or any T,N2-3/M0),
was in 2002 and a large variation existed before and
afterwards (Table 3). The control and Northern region
hospitals with the highest IP show the best implementation
of this recommendation of the guideline while especially
before 2008 patients in the other regions were less likely to
receive adjuvant radiotherapy.
Adjuvant chemotherapy for early stage breast cancer
Patients diagnosed in hospitals in the Rotterdam region
and Northern Netherlands with a low IP received adjuvant
chemotherapy more often for early stage breast cancer
than patients in the control hospitals (Table 3). Guideline
follow-up in the later time-periods is high and differences
between the different hospital categories are small.
Neo adjuvant chemotherapy for T4/M0 breast cancer
Neo-adjuvant chemotherapy for T4/M0 cancer is adminis-
tered to approximately half of the patients in the latest time
period (Table 3). Because this concerns high stage disease,
patient preferences may play an important role in this
variation. Both hospital categories in the Rotterdam region
as well as the Northern low IP hospitals perform better
compared to the control group, with the highest chance of
receiving neo adjuvant chemotherapy in the Rotterdam
hospitals with high IP (OR 2.67, 95% CI 1.74-4.07, Table 3).
Discussion
The results of our study show variation in the multidis-
ciplinary treatment of breast cancer patients in the
Netherlands. No relationship was evident between
variation in multidisciplinary treatment for breast cancer
patients and participating in the external peer review
programme for multidisciplinary cancer care. In the
Northern Netherlands, only the completeness of breast
conserving therapy (stadium I-IIIA) was better in patients
diagnosed in hospitals with a higher IP compared to the
control group. Patients from hospitals with the lowest IP
more often received adjuvant chemotherapy for early stage
breast cancer, neo-adjuvant chemotherapy for T4 breast
cancer and complete breast conserving therapy. In the
Rotterdam region, patients diagnosed in hospitals with
the highest IP were more likely to receive neo-adjuvant
chemotherapy for T4 breast cancer and adjuvant chemo-
therapy for early stage breast cancer. The latter results also
account for patients from hospitals with a low IP from the
Rotterdam region when compared to the control group.
Differences between the regions imply that there are
regional factors that are responsible for the variation.Before 2002, there was regional variation in guidelines.
Table 3 shows that variation decreased in the periods
from 2002–2007 and 2008–2010 but no early adopter
effect was seen in patients from hospitals with a higher
IP. A previous study by van Steenbergen et al. on early
stage breast cancer also showed decreased variation after
the introduction of national evidence-based guidelines in
2002 but variation still persisted. Differences could be
partly explained by hospital characteristics but also by
loco-regional practices. Adjuvant systemic therapy was
found to be mainly influenced by patient and tumour
characteristics [17]. Another study on early stage breast
cancer confirms the important role of the national
evidence-based guidelines and identified age as the most
important factor in the decision whether a patient
receives systemic therapy. They also found the presence of
early and late-adopters amongst hospitals but could not
determine the role of physicians or hospital characteristics
[18]. The programmes in the Northern Netherlands and
Rotterdam region were similar in origin. During the
second cycle in the Rotterdam region, the focus shifted
from the evaluation of basic organisational topics to
implementing plan-do-check-act cycles and the measure-
ment of quality within hospitals. This shift also occurred
in the Northern region but the basic organisational topics
remained part of the programme.
The main weakness of our study was that we had to
use a black box approach concerning the supposed
mechanism through which external peer review on
hospital level exerts its influence on tumour service levels.
Moreover we did not have the possibility of correcting
possible confounding factors such as comorbidity and
patient preference. The gradual spread of the programme
over the country gave us the possibility to use a control
group, creating a quasi-experimental situation. Hospitals
in the control group are likely to have introduced changes
in their organisation too, but we are not aware of similar
programmes that have been used. Hospitals from the high
IP and low IP groups may have had different starting
points concerning organisational quality, unfortunately we
did not have a baseline measurement of organisational
quality. Therefore, we can not answer the question if
hospitals that already had a good multidisciplinary
organisation also performed well on implementing the
recommendations from the programme.
Research in this field is challenging. Besides the
‘quasi-experimental’ situation (due to the gradual
introduction of the programme) our study had multiple
characteristics that helped us to evaluate the impact of
external peer review. In the intervention regions all
hospitals participated in the programme (even though
they did not all give permission to use their data in
this study). Because of this, there was no programme
participation bias. We did not rank the importance of
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of the impact of single recommendations. We were able to
analyse results on a ‘patient level’ because of the reliable
and complete data, including information on treatment,
over a long period of time provided by the Netherlands
Cancer Registry.Conclusion
Our study showed regional differences and did not
reveal benefits in the multidisciplinary treatment of
breast cancer patients being treated in hospitals par-
ticipating in the programme nor did the extent in
which the hospitals implemented the recommenda-
tions seem to matter. Organisation focussed quality
improvement programmes are generally not designed
to directly improve clinical care and in methodological
terms this can still be considered as a “black box
intervention”. Improving the organisation of care
seems a justified goal, but it may be questioned
whether the effort put into it is justified if no clinical
benefits can be shown. If the objective is that external
quality assessment programmes should have a meas-
urable effect on clinical outcomes, the programmes
should change their approach. A better focus on the
actual delivery of clinical care and incorporating reliable
outcome data (from cancer registries) can bridge the
gap between quality improvement and patient outcomes.
Variation in treatment, as shown in our study can be used
as a starting point for quality improvement programmes
for hospitals to work on their organisation and delivery
of care.Additional file
Additional file 1: The external peer review programme for
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